Share to:

 

Nivolumab

Nivolumab
Fab fragment of nivolumab (blue) binding the extracellular domain of PD-1 (purple). From PDB entry 5ggr.
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetPD-1
Clinical data
Trade namesOpdivo
Other namesONO-4538, BMS-936558, MDX1106
AHFS/Drugs.comMonograph
MedlinePlusa614056
License data
Pregnancy
category
Routes of
administration		Intravenous
Drug classImmunotherapy[3]
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life27 days[9]
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6362H9862N1712O1995S42
Molar mass143599.39 g·mol−1

Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer.[2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction cancer.[9][10][2][11][12] It is administered intravenously.[9][10][2]

The most common side effects include fatigue, rash, musculoskeletal pain, pruritus (itching), diarrhea, nausea, asthenia (weakness), cough, dyspnea (shortness of breath), constipation, decreased appetite, back pain, arthralgia (joint pain), upper respiratory tract infection, pyrexia (fever), headache, abdominal pain, and vomiting.[12] Use during pregnancy may harm the baby.[1][2] Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1.[2] It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.[2][3] The most common side effects when used in combination with chemotherapy include peripheral neuropathy (damage to the nerves outside of the brain and spinal cord), nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation and musculoskeletal pain.[11]

Nivolumab was approved for medical use in the United States in 2014.[2][9] It is on the World Health Organization's List of Essential Medicines.[13] It is made using Chinese hamster ovary cells.[14] Nivolumab is the second FDA-approved systemic therapy for mesothelioma[15] and is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.[11]

Medical uses

In the US, nivolumab is indicated to treat:

  • Unresectable or metastatic melanoma[9]
  • Adjuvant treatment of melanoma[9]
  • Metastatic non-small cell lung cancer[9]
  • Malignant pleural mesothelioma[9]
  • Advanced renal cell carcinoma[9]
  • Classical Hodgkin's lymphoma[9]
  • Squamous-cell carcinoma of the head and neck[9]
  • Urothelial carcinoma[9]
  • Microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer[9]
  • Hepatocellular carcinoma[9]
  • Esophageal cancer[9]
  • Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma[9]

Nivolumab is used as a first-line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF,[9] and as a second-line treatment for inoperable or metastatic melanoma following treatment with ipilimumab and, if the cancer has a BRAF mutation, a BRAF inhibitor.[9][16] It is also used to treat metastatic squamous non-small cell lung cancer with progression with or after platinum-based drugs, and for treatment of small cell lung cancer.[9][17] It also used as a second-line treatment for renal cell carcinoma after anti-angiogenic treatment has failed.[9]

Nivolumab is used for primary or metastatic urothelial carcinoma, the most common form of bladder cancer. It can be used for locally advanced or metastatic disease that progresses during or following platinum-based chemotherapy or progresses within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.[18]

Nivolumab is indicated for the adjuvant treatment of melanoma with lymph node involvement as well as in metastatic disease with previous complete resection.[9][19]

The combination of nivolumab with ipilimumab is used for the first-line treatment of adults with inoperable malignant pleural mesothelioma.[9][15]

In April 2021, the US Food and Drug Administration (FDA) approved nivolumab, in combination with certain types of chemotherapy, for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.[11] In May 2021, the FDA approved nivolumab for the treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.[12]

In August 2021, the FDA approved nivolumab for the adjuvant treatment of urothelial carcinoma who are at high risk of recurrence after undergoing radical resection.[20]

In May 2022, the FDA expanded the indication to include the first-line treatment of people with advanced or metastatic esophageal squamous cell carcinoma.[21] In the same year, the FDA approved a combination therapy consisting of relatlimab and nivolumab for the treatment of some cases of advanced melanoma.[22]

In March 2024, the FDA approved nivolumab, in combination with cisplatin and gemcitabine, as a first-line treatment for adults with unresectable or metastatic urothelial carcinoma.[23][24]

In October 2024, the FDA approved nivolumab with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.[25][26]

Side effects

The US FDA prescription label contains warnings regarding increased risk for severe immune-mediated inflammation of the lungs, colon, liver, and kidneys (with accompanying kidney dysfunction), as well as immune-mediated hypothyroidism and hyperthyroidism.[9] Hypothyroidism and hyperthyroidism may affect 8.5% and 3.7% of patients, respectively.[27] Autoimmune diabetes similar to diabetes mellitus type 1 may occur in approximately 2% of people treated with nivolumab.[27]

In trials for melanoma, the following side effects occurred in more than 10% of subjects and more frequently than with chemotherapy alone: rash and itchy skin, cough, upper respiratory tract infections, and peripheral edema. Other clinically important side effects with less than 10% frequency were ventricular arrhythmia, inflammation of parts of the eye (iridocyclitis), infusion-related reactions,[vague] dizziness, peripheral and sensory neuropathy, peeling skin, erythema multiforme, vitiligo, and psoriasis.[9]

In trials for lung cancer, the following side effects occurred in more than 10% of subjects and more frequently than with chemotherapy alone: fatigue, weakness, edema, fever, chest pain, generalized pain, shortness of breath, cough, muscle and joint pain, decreased appetite, abdominal pain, nausea and vomiting, constipation, weight loss, rash, and itchy skin.[9] Levels of electrolytes and blood cells counts were also disrupted.[9]

Pregnancy and breastfeeding

Use during pregnancy may harm the baby.[1][9][2]

Pharmacokinetics

Based on data from 909 patients, the terminal half-life of nivolumab is 26.7 days and steady-state concentrations were reached by 12 weeks when administered at 3 mg/kg every two weeks.[9]: 29  Age, gender, race, baseline LDH, PD-L1 expression, tumor type, tumor size, renal impairment, and mild hepatic impairment do not affect clearance of the drug.[9]: 30 

Mechanism of action

Nivolumab's mechanism of action is based on its role as a monoclonal antibody that selectively binds to the programmed death-1 (PD-1) receptor on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system’s ability to combat malignancies.[28][29] Normally, certain cancer cells exploit the PD-1 pathway to shield themselves from the immune response by expressing programmed death-ligand 1 (PD-L1), which interacts with the PD-1 receptor and inhibits T-cell activation and proliferation. Nivolumab interrupts this interaction by binding to the PD-1 receptor, thereby blocking tumor cells from evading immune detection. This blockade enhances T-cell response, boosts the immune system's anti-tumor activity, and ultimately contributes to the destruction of cancer cells.[28][29]

PD-1 is a protein located on the surface of T cells that have been activated in the body's immune response. Normally, the immune system is controlled in part by certain molecules, such as PD-L1 or PD-L2, which can bind to PD-1. When they do, they prevent the T cell from taking action, which helps to ensure the body does not have an excessive immune reaction.[29] However, many cancer cells take advantage of this system by producing PD-L1 themselves, effectively shutting down T cells and protecting the tumor from an immune attack. Nivolumab interferes with this process—it attaches to PD-1 and prevents PD-L1 from binding to it, which frees the T cells to target and destroy the tumor.[28][29] Approximately 40–50% of melanoma cells express PD-L1. Aside from this, PD-L1 is not commonly found in the body, though it is present in certain areas such as the lining of the respiratory tract and in placental tissue.[16]

Physical properties

Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1.[16] The gamma 1 heavy chain is 91.8% unmodified human design while the kappa light chain is 98.9%.[30]

History

It was invented at Medarex through a research collaboration with Ono.[31] Under the agreement between the companies in 2005, Medarex held an exclusive right of nivolumab in North America, and Ono retained the right in all other countries except North America. Bristol-Myers Squibb acquired Medarex in 2009, for $2.4B.[32][33] Ono received approval from Japanese regulatory authorities to use nivolumab to treat unresectable melanoma in July 2014, which was the first regulatory approval of a PD-1 inhibitor.[34]

Nivolumab received US Food and Drug Administration (FDA) approval for the treatment of melanoma in December 2014.[16][35] In April 2015, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended approval of nivolumab for metastatic melanoma as a monotherapy.[36]

In March 2015, the FDA approved it for the treatment of squamous cell lung cancer.[37]

In June 2015, the EMA granted a marketing authorization valid throughout the European Union.[10]

In November 2015, the FDA approved nivolumab as a second-line treatment for renal cell carcinoma after having granted the application breakthrough therapy designation, fast track designation, and priority review status.[38]

In May 2016, the FDA approved nivolumab for the treatment of people with classical Hodgkin lymphoma who have relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin.[39]

In December 2017, the FDA granted approval to nivolumab for adjuvant treatment of melanoma with involvement of lymph nodes or for metastatic disease with complete resection.[40]

In April 2018, the FDA granted approval to nivolumab in combination with ipilimumab for the first-line treatment of people with intermediate and poor risk advanced renal cell carcinoma.[41]

In June 2018, China's Drug Administration approved nivolumab, the country's first immuno-oncology and the first PD-1 therapy.[42]

In October 2020, the US Food and Drug Administration (FDA) approved the combination of nivolumab with ipilimumab for the first-line treatment of adults with malignant pleural mesothelioma (MPM) that cannot be removed by surgery.[15]

In April 2021, the FDA approved nivolumab, in combination with certain types of chemotherapy, for the initial treatment of people with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.[11]

In March 2024, the FDA approved nivolumab, in combination with cisplatin and gemcitabine, for first-line treatment of adults with unresectable or metastatic urothelial carcinoma.[23] Efficacy was evaluated in CHECKMATE-901 (NCT03036098), a randomized, open-label trial enrolling 608 participants with previously untreated unresectable or metastatic urothelial carcinoma.[23] Participants were randomized (1:1) to receive either nivolumab in combination with cisplatin and gemcitabine (up to six cycles) followed by nivolumab alone for up to two years or cisplatin and gemcitabine (up to six cycles).[23] On both arms, participants discontinuing cisplatin were permitted to receive carboplatin.[23] Randomization was stratified by tumor PD-L1 expression and presence of liver metastasis.[23]

Research

Nivolumab, and other PD-1 inhibitors, appear to be effective in people with brain metastases[43] and for cancer in people with autoimmune diseases.[44]

Hodgkin's lymphoma

In Hodgkin's lymphoma, Reed–Sternberg cells harbor amplification of chromosome 9p24.1, which encodes PD-L1 and PD-L2, and leads to their constitutive expression. In a small clinical study published in 2015, nivolumab elicited an objective response in 87% of a cohort of 20 patients.[45]

The evidence for a favorable effect of nivolumab on overall survival, quality of life, progression-free survival, and complete response among individuals with Hodgkin's lymphoma is uncertain.[46]

Biomarkers

Amplification of chromosome 9p24 may serve as a predictive biomarker in Hodgkin's lymphoma.[45]

Every manufacturer pursuing drug development using monoclonal antibodies against PD-1 has developed assays to measure PD-L1 level as a potential biomarker using the antibody as the analyte-specific reagent. Bristol Myers Squibb partnered with Dako on a nivolumab-based assay. However, as of 2015 the complexity of the immune response had hindered efforts to identify people who would be likely to respond well to PD-1 inhibitors.[45] PD-L1 levels appeared to be dynamic and modulated by several factors, and efforts to correlate PD-L1 levels before or during treatment with treatment response or duration of response had failed to reveal any useful correlations as of 2015.[16]

Lung cancer

In 2016, Bristol Myers Squibb announced the results of a clinical trial in which nivolumab failed to achieve its endpoint and was no better than traditional chemotherapy at treating newly diagnosed lung cancer.[47] Bristol Myers Squibb went on to attempt to gain approval for a combination therapy for lung cancer that included nivolumab and the company's older drug ipilimumab. The application was withdrawn in early 2019 following disappointing results.[48]

Infusion durations of 60 minutes and 30 minutes appear to have similar pharmacokinetics (absorption, distribution, metabolism, and elimination).[49]

Nivolumab is indicated for the treatment of people with metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.[9] CHECKMATE-227[50] tested the combination of nivolumab and ipilimumab in participants with stage IV or recurrent non-small cell lung cancer without previous treatment.[51] Participants with a PD-L1 expression level of 1% or more were randomized in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or standard chemotherapy.[51][50] The chemotherapeutics used were cisplatin or carboplatin combined with gemcitabine for people with squamous-cell non-small cell lung cancer, or pemetrexed for those with nonsquamous disease.[50][51] The overall survival was 17.1, 15.7, and 14.9 months, respectively.[51][50] The participants who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy.[51] The overall survival among that group was 17.2, 15.2 and 12.2 months, respectively.[50]

In June 2023, Bristol Myers Squibb provided positive four-year follow-up results from a phase III study (CheckMate-9LA[52]) of a combination of nivolumab and ipilimumab along with chemotherapy, compared to chemotherapy alone, as first-line treatment in people with metastatic non-small cell lung cancer. The trial found an overall survival of 21% at a median follow-up of 47.9 months among those treated with the dual immunotherapy-based combination compared to 16% of participants treated with chemotherapy alone.[52][53]

Melanoma

PD-L1 is expressed in 40-50% of melanomas.[54] Phase I and II clinical trials have shown nivolumab as a promising and durable treatment option in melanoma as a single agent and in combination with ipilimumab.[16] Phase III trials are ongoing.[55]

In October 2022, the results of a phase III trial, CheckMate -76K, showed that Opdivo reduced the risk of death by 58% as an adjuvant therapy in participants with completely resected stage two melanoma, the most serious type of skin cancer.[55][56]

Urothelial carcinoma

In February 2023, Bristol Myers Squibb reported that the three-year follow-up results from its phase III (CheckMate-274) trial of nivolumab showed significant sustained clinical benefits with nivolumab for the adjuvant treatment of participants with muscle-invasive urothelial carcinoma at a high risk of recurrence after radical resection.[57][58]

See also

References

  1. ^ a b c d "Nivolumab (Opdivo) Use During Pregnancy". Drugs.com. 4 November 2019. Retrieved 11 March 2020.
  2. ^ a b c d e f g h i "Nivolumab Monograph for Professionals". Drugs.com. Retrieved 14 November 2019.
  3. ^ a b "Nivolumab (Opdivo)". Cancer Research UK. Retrieved 15 December 2019.
  4. ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  5. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  6. ^ "Regulatory Decision Summary for Opdivo". Drug and Health Products Portal. 29 December 2023. Retrieved 2 April 2024.
  7. ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
  8. ^ "Opdivo 10 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 24 August 2020. Retrieved 2 October 2020.
  9. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae "Opdivo- nivolumab injection". DailyMed. 17 December 2019. Retrieved 11 March 2020.
  10. ^ a b c d "Opdivo EPAR". European Medicines Agency (EMA). 30 January 2020. Retrieved 11 March 2020.
  11. ^ a b c d e "FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer". U.S. Food and Drug Administration (FDA) (Press release). 16 April 2021. Retrieved 16 April 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  12. ^ a b c "FDA approves nivolumab for resected esophageal or GEJ cancer". U.S. Food and Drug Administration (FDA). 20 May 2021. Retrieved 20 May 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  13. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  14. ^ Rajan A, Kim C, Heery CR, Guha U, Gulley JL (September 2016). "Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers". Human Vaccines & Immunotherapeutics. 12 (9): 2219–31. doi:10.1080/21645515.2016.1175694. PMC 5027703. PMID 27135835.
  15. ^ a b c "FDA Approves Drug Combination for Treating Mesothelioma". U.S. Food and Drug Administration (FDA) (Press release). 2 October 2020. Retrieved 2 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  16. ^ a b c d e f Johnson DB, Peng C, Sosman JA (March 2015). "Nivolumab in melanoma: latest evidence and clinical potential". Therapeutic Advances in Medical Oncology. 7 (2): 97–106. doi:10.1177/1758834014567469. PMC 4346215. PMID 25755682.
  17. ^ Sundar R, Cho BC, Brahmer JR, Soo RA (March 2015). "Nivolumab in NSCLC: latest evidence and clinical potential". Therapeutic Advances in Medical Oncology. 7 (2): 85–96. doi:10.1177/1758834014567470. PMC 4346216. PMID 25755681.
  18. ^ Bushey R (3 February 2017). "Opdivo Gains FDA Approval for Common Bladder Cancer". Drug Discovery & Development. Archived from the original on 4 February 2017.
  19. ^ "FDA grants regular approval to nivolumab for adjuvant treatment of melanoma". U.S. Food and Drug Administration (FDA). 20 December 2017. Retrieved 2 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  20. ^ "FDA approves nivolumab for adjuvant treatment of urothelial carcinoma". U.S. Food and Drug Administration (FDA). 20 August 2021. Retrieved 20 August 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  21. ^ "FDA approves Opdivo". U.S. Food and Drug Administration (FDA). 31 May 2022. Retrieved 31 May 2022.
  22. ^ "FDA approves nivolumab for adjuvant treatment of urothelial carcinoma". U.S. Food and Drug Administration (FDA). 6 April 2023. Retrieved 6 April 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  23. ^ a b c d e f "FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma". U.S. Food and Drug Administration (FDA). 6 March 2024. Retrieved 9 March 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  24. ^ "Bristol Myers Squibb's Opdivo combination receives FDA approval for urothelial carcinoma". PMLiVE. 8 March 2024. Retrieved 8 March 2024.
  25. ^ "FDA Roundup: October 4, 2024". U.S. Food and Drug Administration (FDA) (Press release). 4 October 2024. Retrieved 8 October 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  26. ^ "FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer". U.S. Food and Drug Administration (FDA). 3 October 2024. Retrieved 15 October 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  27. ^ a b de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B (March 2019). "A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors". Hormone and Metabolic Research. 51 (3): 145–156. doi:10.1055/a-0843-3366. PMID 30861560.
  28. ^ a b c Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–64. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
  29. ^ a b c d Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
  30. ^ WHO Drug Information, Vol. 26, No. 2, 2012. Proposed INN List 107
  31. ^ Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. (September 2014). "In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates". Cancer Immunology Research. 2 (9): 846–56. doi:10.1158/2326-6066.CIR-14-0040. PMID 24872026.
  32. ^ Allison M (September 2009). "Bristol-Myers Squibb swallows last of antibody pioneers". Nature Biotechnology. 27 (9): 781–3. doi:10.1038/nbt0909-781. PMID 19741612. S2CID 205270797.
  33. ^ Carroll J (23 July 2009). "Bristol-Myers to buy Medarex for $2.1B". Fierce Biotech. Retrieved 8 January 2024.
  34. ^ Carroll J (7 July 2014). "Anti-PD-1 cancer star nivolumab wins world's first regulatory approval". Fierce Biotech. Retrieved 15 October 2024.
  35. ^ "FDA approves Opdivo for advanced melanoma" (Press release). U.S. Food and Drug Administration (FDA). 22 December 2014. Archived from the original on 13 February 2017. Retrieved 16 December 2019.
  36. ^ "New treatment for advanced melanoma". European Medicines Agency (EMA) (Press release). 24 April 2015. Retrieved 11 March 2020.
  37. ^ "FDA expands approved use of Opdivo to treat lung cancer" (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 5 March 2015. Retrieved 4 March 2015.
  38. ^ "FDA approves Opdivo to treat advanced form of kidney cancer". U.S. Food and Drug Administration (FDA) (Press release). 23 November 2015. Archived from the original on 25 January 2018. Retrieved 2 October 2020.
  39. ^ "Nivolumab (Opdivo) for Hodgkin Lymphoma". U.S. Food and Drug Administration (FDA). 17 May 2016.
  40. ^ "FDA grants regular approval to nivolumab for adjuvant treatment of melanoma". U.S. Food and Drug Administration (FDA). 21 December 2017. Retrieved 12 April 2018.
  41. ^ "FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma". U.S. Food and Drug Administration (FDA). Retrieved 20 April 2018.
  42. ^ "Bristol-Myers' Opdivo ushers in a new era as the first I-O therapy approved in China | FiercePharma". www.fiercepharma.com. 15 June 2018. Retrieved 19 June 2018.
  43. ^ Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, et al. (May 2018). "Cancer immunotherapy in patients with brain metastases". Cancer Immunology, Immunotherapy. 67 (5): 703–711. doi:10.1007/s00262-018-2146-8. hdl:11573/1298742. PMC 11028279. PMID 29520474. S2CID 3782427.
  44. ^ Donia M, Pedersen M, Svane IM (April 2017). "Cancer immunotherapy in patients with preexisting autoimmune disorders". Seminars in Immunopathology. 39 (3): 333–337. doi:10.1007/s00281-016-0595-8. PMID 27730287. S2CID 3387103.
  45. ^ a b c Sharma P, Allison JP (April 2015). "The future of immune checkpoint therapy". Science. 348 (6230): 56–61. Bibcode:2015Sci...348...56S. doi:10.1126/science.aaa8172. PMID 25838373. S2CID 4608450.
  46. ^ Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, et al. (Cochrane Haematological Malignancies Group) (July 2018). "Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)". The Cochrane Database of Systematic Reviews. 2018 (7): CD012556. doi:10.1002/14651858.CD012556.pub2. PMC 6513229. PMID 30001476.
  47. ^ Loftus P, Rockoff JD, Steele A (5 August 2016). "Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study". The Wall Street Journal. ISSN 0099-9660. Retrieved 21 August 2016.
  48. ^ Erman M (24 January 2019). "Bristol-Myers has Opdivo lung cancer setback as sales beat estimates". Reuters. Retrieved 24 January 2019.
  49. ^ Waterhouse D, Horn L, Reynolds C, Spigel D, Chandler J, Mekhail T, et al. (April 2018). "Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153". Cancer Chemotherapy and Pharmacology. 81 (4): 679–686. doi:10.1007/s00280-018-3527-6. PMID 29442139. S2CID 3906670.
  50. ^ a b c d e Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. (November 2019). "Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer". The New England Journal of Medicine. 381 (21): 2020–2031. doi:10.1056/NEJMoa1910231. PMID 31562796.
  51. ^ a b c d e Nasser NJ, Gorenberg M, Agbarya A (November 2020). "First line Immunotherapy for Non-Small Cell Lung Cancer". Pharmaceuticals. 13 (11): 373. doi:10.3390/ph13110373. PMC 7695295. PMID 33171686.
  52. ^ a b "A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer". 11 November 2022.
  53. ^ "Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer". Bristol Myers Squibb (Press release). Retrieved 5 June 2023.
  54. ^ Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. (August 2002). "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion". Nature Medicine. 8 (8): 793–800. doi:10.1038/nm730. PMID 12091876. S2CID 27694471.
  55. ^ a b "CA209-76K". EU Clinical Trials Register. Retrieved 20 October 2022.
  56. ^ "Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial". Bristol Myers Squibb (Press release). Retrieved 20 October 2022.
  57. ^ Clinical trial number NCT02632409 for "A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)" at ClinicalTrials.gov
  58. ^ "BMS reports positive three-year results for Opdivo to treat bladder cancer". PMLive. 21 February 2023. Retrieved 22 February 2023.
  • "Nivolumab". NCI Drug Dictionary. National Cancer Institute.
  • "Nivolumab". National Cancer Institute. 7 January 2015.
  • Clinical trial number NCT01721746 for "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)" at ClinicalTrials.gov
  • Clinical trial number NCT01721772 for "Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)" at ClinicalTrials.gov
  • Clinical trial number NCT01844505 for "Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)" at ClinicalTrials.gov
  • Clinical trial number NCT02388906 for "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)" at ClinicalTrials.gov
  • Clinical trial number NCT02477826 for "An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)" at ClinicalTrials.gov
  • Clinical trial number NCT03215706 for "A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)" at ClinicalTrials.gov
  • Clinical trial number NCT01642004 for "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)" at ClinicalTrials.gov
  • Clinical trial number NCT01673867 for "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)" at ClinicalTrials.gov
  • Clinical trial number NCT02899299 for "Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)" at ClinicalTrials.gov
  • Clinical trial number NCT02231749 for "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)" at ClinicalTrials.gov
  • Clinical trial number NCT03141177 for "A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)" at ClinicalTrials.gov
  • Clinical trial number NCT01668784 for "Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)" at ClinicalTrials.gov
  • Clinical trial number NCT02181738 for "Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (CheckMate 205)" at ClinicalTrials.gov
  • Clinical trial number NCT01592370 for "An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma" at ClinicalTrials.gov
  • Clinical trial number NCT02105636 for "Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)" at ClinicalTrials.gov
  • Clinical trial number NCT02387996 for "A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer" at ClinicalTrials.gov
  • Clinical trial number NCT02060188 for "An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)" at ClinicalTrials.gov
  • Clinical trial number NCT01658878 for "An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (CheckMate040)" at ClinicalTrials.gov
  • Clinical trial number NCT02743494 for "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)" at ClinicalTrials.gov
  • Clinical trial number NCT02569242 for "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer" at ClinicalTrials.gov
  • Clinical trial number NCT02872116 for "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)" at ClinicalTrials.gov
  • Clinical trial number NCT02632409 for "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)" at ClinicalTrials.gov
Kembali kehalaman sebelumnya